Your browser doesn't support javascript.
loading
Adding SGLT2 Cotransporter Inhibitor to PPARγ Activator Does Not Provide an Additive Effect in the Management of Diabetes-Induced Vascular Dysfunction.
Cinakova, Aneta; Krenek, Peter; Klimas, Jan; Kralova, Eva.
Affiliation
  • Cinakova A; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia.
  • Krenek P; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia.
  • Klimas J; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia.
  • Kralova E; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia.
Pharmacology ; 108(6): 565-575, 2023.
Article in En | MEDLINE | ID: mdl-37844554
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Experimental / Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors Limits: Animals Language: En Journal: Pharmacology Year: 2023 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Experimental / Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors Limits: Animals Language: En Journal: Pharmacology Year: 2023 Document type: Article Affiliation country: